Loading…
Top-line results from oncology MoA studies revealed.
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced top-line results from its oncology mechanism of action (MoA) studies. The studies demonstrated that a combination of Aramchol, Stivarga, and Metformin enhanced the killing of gastrointestinal (GI) tumor cells both in-vivo and in-vitro.
The company did not provide specific numerical data or comparisons in this announcement. The results indicate a potential therapeutic benefit of the drug combination in oncology applications.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.